Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PG2 Treatment for Reduction of Chemotherapy-Induced Toxicity and Encouraging Compliance With Chemotherapy Among Stage II/III Breast Cancer Patients Receiving Adjuvant Chemotherapy

NCT03314805 is registered in ClinicalTrials.gov with PhytoHealth Corporation as lead sponsor.

NCT NCT03314805
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03314805 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PG2 Treatment for Reduction of Chemotherapy-Induced Toxicity and Encouraging Compliance With Chemotherapy Among Stage II/III Breast Cancer Patients Receiving Adjuvant Chemotherapy
Lead sponsor
PhytoHealth Corporation
Phase
Phase 2
Overall status
Completed
Start date
March 1, 2018
Completion date
August 27, 2021
Enrollment
67 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

cancer-related fatigue, neutropenia, malignant